Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MENOSTAR vs EVAMIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrogen receptor agonist; binds to estrogen receptors, leading to gene transcription and physiological effects.
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
Treatment of moderate to severe vasomotor symptoms due to menopause,Off-label: Prevention of postmenopausal osteoporosis (not FDA-approved for this indication)
One Menostar (estradiol 14 mcg/day) transdermal system applied to the lower abdomen once weekly (every 7 days).
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
Terminal half-life of estradiol is approximately 12-14 hours; with MENOSTAR (estradiol vaginal ring), systemic absorption is minimal, and the effective half-life for local effects is extended by continuous release over 90 days.
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
Hepatic via CYP3A4; undergoes enterohepatic recirculation.
Estradiol is primarily metabolized in the liver via CYP3A4 and other cytochrome P450 enzymes. It is also metabolized in the gastrointestinal tract and skin. Major metabolites include estrone and estriol, which are conjugated (sulfates and glucuronides) and excreted in urine.
Renal (primarily as glucuronide and sulfate conjugates), ~40-60% of a dose excreted in urine; fecal excretion accounts for approximately 10-20% as unabsorbed drug or metabolites.
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
Estradiol is approximately 98% bound to sex hormone-binding globulin (SHBG) and albumin.
80% bound to albumin and alpha-1-acid glycoprotein
Apparent Vd of estradiol is approximately 1.2 L/kg; this large volume reflects extensive distribution into tissues, but for MENOSTAR, systemic distribution is limited due to low absorption.
3-5 L/kg; indicates extensive tissue distribution
Vaginal route: minimal systemic bioavailability (<10% of the dose absorbed systemically due to first-pass hepatic metabolism and local action).
Intranasal: 70%; oral: not applicable (first-pass metabolism)
No dosage adjustment required for renal impairment; estradiol pharmacokinetics not significantly altered in renal disease.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in patients with impaired liver function or active liver disease; no adjustment guidelines available for Child-Pugh classes.
Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). No data for mild impairment; use with caution.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for use in pediatric patients. Safety and efficacy not established.
No specific dosage adjustment recommended; however, use the lowest effective dose for the shortest duration due to increased risk of thromboembolic events and malignancy in elderly women.
No specific dose adjustment recommended; however, initiate at lowest effective dose due to increased risk of adverse effects (e.g., thromboembolism, malignancy) in elderly.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen use increases risk of endometrial hyperplasia and carcinoma. Concomitant progestin therapy is recommended.
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Use of unopposed estrogens is associated with an increased risk of endometrial hyperplasia and carcinoma. Additionally, estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and breast cancer with estrogen-alone therapy.
Endometrial hyperplasia and carcinoma,Cardiovascular disorders (e.g., stroke, DVT, PE),Breast cancer risk,Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hereditary angioedema
Risk of endometrial cancer: Use progestin in women with intact uterus.,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, especially in smokers and older women.,Breast cancer: Increased risk with long-term use.,Dementia: Increased risk in women ≥65 years old.,Gallbladder disease.,Hypercalcemia in patients with breast cancer and bone metastases.,Retinal vascular thrombosis: Discontinue if sudden vision loss occurs.,Fluid retention: Use with caution in patients with conditions exacerbated by edema.,Hypothyroidism: May need increased thyroid replacement dose.,Hepatic impairment: Contraindicated in severe liver disease.
Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except for appropriately selected patients),Known or suspected estrogen-dependent neoplasia,Active DVT, PE, or history of these conditions,Active arterial thromboembolic disease or history of these conditions (e.g., stroke, MI),Known anaphylactic reaction or angioedema to estrogens,Hepatic impairment or disease,Known or suspected pregnancy
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-sensitive neoplasia,Active or history of deep vein thrombosis or pulmonary embolism,Active or history of arterial thromboembolic disease (e.g., stroke, MI),Known thrombophilic disorders (e.g., Protein C, S, or antithrombin deficiency),Hepatic impairment or disease,Pregnancy,Hypersensitivity to estradiol or any ingredient
Grapefruit and grapefruit juice may increase estradiol systemic absorption via CYP3A4 inhibition; avoid concomitant consumption. No other significant food interactions.
Grapefruit and grapefruit juice may increase estradiol levels; avoid excessive consumption. No other significant food interactions reported.
First trimester: Use contraindicated due to risk of urogenital tract abnormalities and cardiovascular defects; second and third trimester: Estrogen exposure associated with increased risk of endometrial adenocarcinoma and other malignancies in female offspring; no adequate studies; use only if clearly needed.
Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and potential long-term reproductive tract effects in offspring. Use is not recommended at any gestational stage.
Excreted in breast milk in small amounts; M/P ratio not reported for conjugated estrogens; may interfere with lactation; not recommended in breastfeeding women; consider alternative therapy.
Estradiol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.1-0.2. Studies show low concentrations in milk, but long-term effects on the infant are unknown. Evamist is not recommended during breastfeeding due to potential hormonal disruption and reduced milk production.
Not indicated for use in pregnancy; no dose adjustment guidelines exist for pregnancy because of contraindication; pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may alter efficacy but no established dosing recommendations.
No dosing adjustments applicable as Evamist is contraindicated in pregnancy. In the non-pregnant state, no dosage adjustment is needed. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) are not relevant as the drug should not be used.
MENOSTAR (estradiol vaginal ring) delivers low-dose estrogen locally for vulvovaginal atrophy. Systemic absorption minimal due to vaginal route; avoids first-pass metabolism. Insert ring high in vagina; replace every 90 days. Do not use in patients with known or suspected breast cancer, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active DVT/PE, or history of same. Monitor for endometrial hyperplasia in uterus intact women; consider adding progestin if needed.
Apply EVAMIST to clean, dry, intact skin of the axilla or inner thigh. Avoid application to irritated or broken skin. Rotate application sites to minimize local skin reactions. Do not apply to the breast or vaginal area. For optimal absorption, wait at least 1 hour after application before showering or swimming. Monitor serum estradiol levels if inadequate symptom relief or adverse effects occur.
Insert the ring high into the vagina as directed for 90-day continuous use.,The ring may be removed during intercourse; rinse with lukewarm water and reinsert promptly.,Do not use oils or lubricants containing petroleum jelly which may damage the ring.,Report any unusual vaginal bleeding, pain, or signs of thromboembolism (leg pain, chest pain, shortness of breath).,This medication does not protect against STIs or pregnancy; no systemic contraception provided.
Apply the gel to clean, dry skin on your armpit or inner thigh.,Rotate application sites daily to avoid skin irritation.,Avoid applying to the breast or vaginal area.,Do not wash the application area for at least 1 hour after applying.,Keep away from children and pets; wash hands thoroughly after application.,Do not use if you are pregnant, breastfeeding, or have a history of certain cancers.,Report any unusual vaginal bleeding, breast lumps, or signs of blood clots immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MENOSTAR vs EVAMIST, answered by our medical review team.
MENOSTAR is a Estrogen Replacement Therapy that works by Estrogen receptor agonist; binds to estrogen receptors, leading to gene transcription and physiological effects.. EVAMIST is a Estrogen Replacement that works by Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MENOSTAR and EVAMIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MENOSTAR is: One Menostar (estradiol 14 mcg/day) transdermal system applied to the lower abdomen once weekly (every 7 days).. The standard adult dose of EVAMIST is: 1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MENOSTAR and EVAMIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MENOSTAR is classified as Category C. First trimester: Use contraindicated due to risk of urogenital tract abnormalities and cardiovascular defects; second and third trimester: Estrogen exposure associated with increas. EVAMIST is classified as Category C. Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. S. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.